Search hospitals > Illinois > Peru
Illinois CancerCare-Peru
Claim this profilePeru, Illinois 61354
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
385 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Peru is a medical facility located in Peru, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Peru is involved with conducting 385 clinical trials across 474 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Bryan A. FallerCrossroads Cancer Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
239 reported clinical trials
297 drugs studied
James L. WadeDecatur Memorial Hospital4 years of reported clinical research
Studies Breast Cancer
Studies Bladder Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Illinois CancerCare-Peru
Lung Cancer
Prostate Cancer
Breast Cancer
Cancer
Pancreatic Cancer
Breast cancer
Kidney Cancer
Bladder Cancer
Multiple Myeloma
Esophageal cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting2 awards Phase 310 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Peru?
Illinois CancerCare-Peru is a medical facility located in Peru, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Peru is involved with conducting 385 clinical trials across 474 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Peru located?
**Illinois CancerCare - Peru Location**
- **Address:** 4391 Venture Dr, Suite 1, Peru, IL 61354
- **Part of:** Valley Regional Cancer Center
- **Contact:** For more information, visit their website or call (815) 223-7010.
Who should I call to ask about financial aid or insurance network?
For inquiries about financial assistance and insurance matters at Illinois CancerCare-Peru, please contact the main line at (217) 383-3311. The Illinois CancerCare Foundation also provides financial assistance for tumor sequencing and targeted oral therapies for eligible patients.
What insurance does Illinois CancerCare-Peru accept?
Illinois CancerCare-Peru accepts a wide range of insurance plans, including but not limited to Medicare, Aetna (HMO, PPO, POS), BCBS of Illinois (PPO, POS, EPO, Classic Blue HMO, HMOI, Blue Advantage HMO), Beech Street PPO, Cigna/Great West Healthcare (HMO, PPO, POS, Open Access), and United Health Care. It is crucial to confirm that your physicians are within your plan's network. Additionally, pre-certification may be required for those in an HMO or PPO plan.
What awards or recognition has Illinois CancerCare-Peru received?
Illinois CancerCare-Peru, located in Peru, Illinois, is nationally recognized for its excellence in clinical research, being one of the top enrollers for the Alliance for Clinical Trials in Oncology in 2015. Additionally, it has earned certification from the Quality Oncology Practice Initiative (QOPI®) for meeting stringent national standards in cancer care.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.